Login / Signup

Comparison of Plasma Concentrations of Posaconazole with the Oral Suspension and Tablet in Korean Patients with Hematologic Malignancies.

Hyeon Jeong SuhIn Ho KimJoo-Youn ChoSang In ParkSeo Hyun YoonJeong Ok LeeYoungil KohKyoung-Ho SongPyeong Gyun ChoeKyung-Sang YuEu-Suk KimHong Bin KimSoo-Mee BangNam Joong KimSang Hoon SongPyoeng Gyun ChoeMyoung-don Oh
Published in: Infection & chemotherapy (2017)
The posaconazole tablet formulation was developed to have improved bioavailability compared to the oral suspension. Here, we compared posaconazole plasma concentration (PPC) with the posaconazole oral suspension versus the tablet in Korean patients undergoing remission induction chemotherapy for hematologic malignancies. PPC was measured at 3, 8, and 15 days of treatment with the oral suspension (174 patients) or the tablet (40 patients). At all time-points, mean PPC was significantly higher with the tablet compared to the oral suspension. Our findings suggest that posaconazole tablets generate an optimal PPC earlier and in more patients than the oral suspension among Korean patients.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • patients undergoing
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • rheumatoid arthritis
  • patient reported outcomes
  • combination therapy